t(15;17)(q24;q21) PML/RARA by Poddighe, Pino J & Weghuis, Daniel Olde
Leukaemia Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(12) 620 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
t(15;17)(q24;q21) PML/RARA 
Pino J. Poddighe, Daniel Olde Weghuis 
Department of Clinical Genetics, VU University Medical Center, Amsterdam (PJP); Department of 
Human Genetics, Radboud University Nijmegen Medical Centre (DOW), The Netherlands. 
p.poddighe@vumc.nl; Daniel.OldeWeghuis@radboudumc.nl
Published in Atlas Database: March 2016 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t1517ID1035.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/66951/03-2016-t1517ID1035.pdf 
DOI: 10.4267/2042/66951
This article is an update of : 
Huret JL, Chomienne C. t(15;17)(q22;q21). Atlas Genet Cytogenet Oncol Haematol 1998;2(3) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on t(15;17)(q24;q21), with data on clinics, 
and the genes involved. 
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Identity 
The translocation, formerly known as 
t(15;17)(q22;q21) or t(15;17)(q22;q12), has been 
renamed t(15;17)(q24;q21), since PML is located in 
chromosome band 15q24, and RARA in 
chromosome band 17q21. 
t(15;17)(q24;q21) G- banding (left) - 2 top left: Courtesy Jean-Luc Lai and Alain Vanderhaegen, 2 bottom left: Courtesy Roland 
Berger ; R-banding (right) - top: Editor, middle: Courtesy Christiane Charrin, bottom: Courtesy Roland Berger. 
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t(15;17)(q24;21) is associated conbsistently with AML M3. This chromosomal abnormality first appeared to be confined to the 
characteristic or morphologically typical M3 AML or "hypergranular promyelocytic leukemia", defined by bone marrow 
replacement with highly granulated blast cells. The nuclear size and shape is irregular and highly variable; they are often kidney-
shaped or bilobed. The cytoplasm is completely occupied by densely packed or even coalescent large granules, staining bright 
pink, red or purple by MGG. In some cells the cytoplasm is filled with fine dust-like granules. Characteristic cells containing 
bundles of Auer rods ("faggot cells") randomly distributed in the cytoplasm, although frequent, are not present in all cases. Auer 
rods in M3 are usually larger than in other AML and they may have a characteristic morphology at the ultrastructural level. In 
some cases, the cytoplasmic granules are so large and/or numerous that they totally obscure the cell, rendering the nuclear 
cytoplasmic limit indistinct. In M3 AML, MPO is always strongly positive in all blast cells, with the reaction product covering the 
whole cytoplasm and often the nucleus too - Text and iconography Courtesy Georges Flandrin 2001. 
 
Clinics and pathology 
Disease 
Acute promyelocytic leukaemia (APL), subtype of 
acute myeloid leukaemia (AML). Mostly de novo; a 
very few cases of t(15;17) in therapy-related 
leukaemia (t-APL) have been reported. In sporadic 
cases the t(15;17) can be present in chronic 
myelogenous leukemia (CML) in myeloid blast 
crisis as an additional abnormality to the 
t(9;22)(q34;q11.2). 
Phenotype/cell stem origin 
t(15;17) is quasi pathognomonic of APL. Both 
hypergranular or "typical" APL and microgranular 
(hypogranular) types exist. 
Epidemiology 
Found in 10% of adult AML; annual incidence: 1 per 
106, similar to the incidence of the t(8;21)(q22;q22). 
The disease can occur at any age, but patients are 
predominantly adult in mid-life; sex ratio 1M/1F 
(WHO 2008). 
Clinics 
Typical and microgranular APL are frequently 
associated with disseminated intravascular 
coagulation (DIC). In microgranular APL, unlike 
typical APL, the leukocyte count is very high, with 
rapid doubling time. WBC and platelets may be 
lower than in other AMLs. 
Cytology 
Large cells with myeloperoxidase positive 
cytoplasmic granulations (microgranular forms are 
called variant or hypogranular APL, and are often 
hyperleucocytic); bundles of Auer rods. 
The typical morphology shows abnormal, usually 
bilobed hypergranular promyelocytes.  
Sudan Black (SB) is always strongly positive in all 
blast cells (WHO 2008). 
Treatment 
One of the rare leukaemias where treatment is an 
emergency, as intra vascular coagulation is 
prominent, causing a high rate (10 to 40%) of early 
mortality, mainly due to cerebral haemorrhage. With 
the recent differentiation therapy using all-trans 
retinoic acid ATRA (with combined cytotoxic 
chemotherapy or arsenic trioxide (ATO)), complete 
remission (CR) is obtained in more than 90% of 
cases; this is the only cancer which, to date, can be 
treated by differentiation therapy. 
Prognosis 
The prognosis in APL, treated optimally with ATRA 
and an anthracycline, is more favourable than for any 
other AML cytogenetic subtype, and cases of 
relapsed or refractory APL show a generally good 
response with arsenic trioxide therapy.  
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FISH with the LSI PML/RARA Dual Color Dual Fusion Translocation Probe (Abbott) on a bone marrow cell sample, showing a 
metaphase spread and one interphase nucleus with two PML-RARA fusion signals (arrows), and one normal interphase cell with 
two red and two green signals. Courtesy Hossein Mossafa. 
 
 
Expression of DC56 is associated with a less 
favourable prognosis, (Ferrara et al 2000) while the 
prognostic significance of FLT3 -ITD mutations in 
this disease remains unclear (Kuchenbauer et al 
2005). Survival at 1 yr and at 3 yrs are stable at 70%, 
instead of a 30 to 40% 3 yr survival previously. 
Cytogenetics 
Cytogenetics morphological 
Classic translocation t(15;17)(q24;q21). The 
translocation may be overlooked in traditional 
karyotyping. Interphase FISH is indicated, 
preferably urgent (within 8 hours) on bone marrow 
aspirate cells (see Figure 1).  
Although primary anomaly in most cases, t(15;17) 
can also occur in rare occurrences at acutisation (of 
promyelocytic type, of course) of a CML with the 
usual t(9;22). 
Additional anomalies 
Secondary cytogenetic abnormalities are noted in 
about 40% of cases, +8 most frequent (10-15%); del 
(7q) ; del(9q) rare. 
Genes involved and 
proteins 
Note 
The sensitivity of APL cells (both hypergranular and 
hypogranular forms) to ATRA has led to the 
discovery that the retinoic acid receptor alpha  
(RARA) gene on chromosome band 17q21 fuses 
with a nuclear regulatory factor gene on 
chromosome band 15q24 (PML gene) giving rise to 
a PML-RARA fusion gene product.  
Rare cases of APL lacking the classic translocation 
in routine cytogenetic studies have been described 
with complex variant translocations (true variants) 
involving both chromosomes 15 and 17 with an 
additional chromosome (three way translocations) or 
with submicroscopic insertion of RARA into PML 
leading to the expression of the PML-RARA 
transcript; these latter cases are considered as cryptic 
or masked t(15;17)(q24;q21). Morphological 
analysis shows no major differences between the 
t(15;17)(q24;q21) positive group and the PML-
RARA positive patients without t(15;17)(q24;q21).  
Three way translocations demonstrated that the 
crucial event lies on der(15), which receives the end 
part of chromosome 17.  
A subset of patients, often with morphological 
features resembling APL, show variant 
translocations involving RARA (17q21). These 
variant fusion partners include ZBTB16 (previously 
known as PLZF at 11q23) in t(11;17)(q23;q21), 
NPM1 at 5q35 in t(5;17)(q32;q12), and NUMA1 at 
11q13 in t(11;17)(q13;q21) ID: 1126> and STAT5B 
at 17q11.2 in dup(17)(q12q21). Some APL variants, 
including t(11;17)(q23;q12) with ZBTB16-RARA 
and cases with STAT5B-RARA fusions are resistant 
to ATRA.  
Mutations involving FLT3 occur in 34-45% of APL. 
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PML and RARA breakpoints in the t(15;17) / 5' PML - 3' RARA fusion gene - Courtesy Hossein Mossafa. 
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PML (promyelocytic leukemia) 
Location 
15q24.1 
DNA/RNA 
Numerous splices in 3'. 
Protein 
Nuclear protein; contains zinc fingers and a leucine 
zipper; transcription factor. 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
Wide expression; nuclear receptor; binds specific 
DNA sequences: HRE (hormone response 
elements); ligand and dimerization domain; role in 
growth and differentiation. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Variable breakpoint in PML between intron 3 and 
exon 7a; constant breakpoint in intron 2 of RARa. 
Transcript 
5' PML -3' RARa transcript is found in all cases, and 
5' RARa - 3' PML transcript is detected in 2/3 of 
cases. 
Fusion protein 
Description 
Variable, as breakpoints in PML are variable; e.g.: 
932 amino acids; 103 kDa; N-term PML, with the 
DNA binding and the dimerization domains fused to 
most of RARa with the DNA and retinoid binding 
regions. 
 
 
 
Oncogenesis 
Abnormal retinoic acid receptor with a dominant 
effect over RARa, antagonizing differentiation. 
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